#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14846	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2052	717.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1442	1442	C	820	C	774	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14846	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2052	717.1	0	HET	.	.	.	C207T	.	207	207	C	465	465	C	872	C,T	653,159	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26874	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3538	755.6	0	.	n	.	0	T695C	SNP	695	695	T	1106	1106	C	819	C,T,A	772,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26874	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3538	755.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	2049	2049	G	846	G	784	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26874	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3538	755.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2382	2382	C	851	C,G	800,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26874	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3538	755.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2456	2456	A	839	A	799	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26874	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3538	755.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3008	3008	C	893	C,A	837,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2096	folP	855	855	100.0	folP.l6.c30.ctg.1	1663	125.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1065	1067	AGC	220;220;218	A;G;C	210;210;207	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5432	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3618	149.8	1	SNP	p	S91F	1	.	.	271	273	TTC	662	664	TTC	177;177;177	T;T;C	167;167;164	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5432	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3618	149.8	1	SNP	p	D95G	1	.	.	283	285	GGC	674	676	GGC	177;178;181	G;G;C	168;170;169	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5432	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3618	149.8	1	SNP	p	G95N	0	.	.	283	285	GGC	674	676	GGC	177;178;181	G;G;C	168;170;169	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1682	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1411	118.5	1	SNP	p	G45D	0	.	.	133	135	GGC	443	445	GGC	234;234;231	G,A;G;C	219,1;218;217	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	806	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1110	72.1	0	.	n	.	0	A197.	DEL	197	197	A	596	596	A	185	A	177	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2876	197.2	1	SNP	p	D86N	0	.	.	256	258	GAC	508	510	GAC	227;226;227	G;A;C	212;206;213	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2876	197.2	1	SNP	p	R87I	0	.	.	259	261	CGT	511	513	CGT	226;226;224	C;G;T	214;214;210	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2876	197.2	1	SNP	p	R87W	0	.	.	259	261	CGT	511	513	CGT	226;226;224	C;G;T	214;214;210	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2876	197.2	1	SNP	p	S87R	1	.	.	259	261	CGT	511	513	CGT	226;226;224	C;G;T	214;214;210	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5690	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2876	197.2	1	SNP	p	S88P	0	.	.	262	264	TCC	514	516	TCC	225;223;224	T;C;C	209;212;213	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4232	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2708	155.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1560	1562	GGC	240;238;235	G;G;C	225;222;216	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1155	1157	GCC	195;195;194	G;C;C	186;183;183	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1158	1160	ATG	194;193;190	A;T;G	183;181;182	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1170	1172	ACC	188;186;186	A;C;C	180;177;178	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1170	1172	ACC	188;186;186	A;C;C	180;177;178	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1671	1673	ACC	227;228;231	A;C;C	207;210;212	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1725	1727	GCG	214;213;219	G;C;G	202;202;207	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1725	1727	GCG	214;213;219	G;C;G	202;202;207	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1848	1850	GGT	199;198;197	G,T;G;T	184,1;186;183	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1857	1859	AGC	189;187;184	A;G;C	177;176;172	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4060	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	171.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1875	1877	CCG	160;163;165	C,G;C,G;G	118,10;120,2;129	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6032	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3239	185.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1709	1711	CCG	211;214;209	C;C;G	188;196;184	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2616	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1895	137.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	592	592	C	184	C	171	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2880	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1496	190.2	1	SNP	p	G120K	1	.	.	358	360	AAG	613	615	AAG	231;228;229	A;A;G,T	213;214;207,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2880	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1496	190.2	1	SNP	p	N121D	0	.	.	361	363	AAC	616	618	AAC	231;231;231	A;A;C,A	216;218;214,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2880	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1496	190.2	1	SNP	p	A121N	1	.	.	361	363	AAC	616	618	AAC	231;231;231	A;A;C,A	216;218;214,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10548	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4882	215.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1138	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1004	111.9	1	SNP	p	V57M	1	.	.	169	171	ATG	491	493	ATG	227;228;229	A;T;G	214;214;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
